Cargando…

Potential two-step proteomic signature for Parkinson's disease: Pilot analysis in the Harvard Biomarkers Study

INTRODUCTION: We sought to determine if our previously validated proteomic profile for detecting Alzheimer's disease would detect Parkinson's disease (PD) and distinguish PD from other neurodegenerative diseases. METHODS: Plasma samples were assayed from 150 patients of the Harvard Biomark...

Descripción completa

Detalles Bibliográficos
Autores principales:	O'Bryant, Sid E., Edwards, Melissa, Zhang, Fan, Johnson, Leigh A., Hall, James, Kuras, Yuliya, Scherzer, Clemens R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Special Section: Blood-Based Biomarkers for Alzheimer's Disease & Related Dementias. (Editor: Henrik Zetterberg)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6502745/ https://www.ncbi.nlm.nih.gov/pubmed/31080873 http://dx.doi.org/10.1016/j.dadm.2019.03.001

Ejemplares similares

A proteomic signature for dementia with Lewy bodies
por: O'Bryant, Sid E., et al.
Publicado: (2019)

Aβ and tau structure-based biomarkers for a blood- and CSF-based two-step recruitment strategy to identify patients with dementia due to Alzheimer's disease
por: Nabers, Andreas, et al.
Publicado: (2019)

Serum levels of proteins involved in amyloid-β clearance are related to cognitive decline and neuroimaging changes in mild cognitive impairment
por: Liu, Shan, et al.
Publicado: (2019)

Posttraumatic stress disorder and total amyloid burden and amyloid-β 42/40 ratios in plasma: Results from a pilot study of World Trade Center responders
por: Clouston, Sean A.P., et al.
Publicado: (2019)

Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease
por: Fossati, Silvia, et al.
Publicado: (2019)

Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition
por: Risacher, Shannon L., et al.
Publicado: (2019)

Complement protein levels in plasma astrocyte-derived exosomes are abnormal in conversion from mild cognitive impairment to Alzheimer's disease dementia
por: Winston, Charisse N., et al.
Publicado: (2019)

Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers
por: Rózga, Małgorzata, et al.
Publicado: (2019)

Sets of coregulated serum lipids are associated with Alzheimer's disease pathophysiology
por: Barupal, Dinesh Kumar, et al.
Publicado: (2019)

Plasma lipocalin-2 levels in the preclinical stage of Alzheimer's disease
por: Eruysal, Emily, et al.
Publicado: (2019)

Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals
por: Benedet, Andréa L., et al.
Publicado: (2019)

Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition
por: Osborn, Katie E., et al.
Publicado: (2019)

Blood-based biomarkers for Alzheimer's disease and related dementias: Keys to success and things to consider
por: Zetterberg, Henrik, et al.
Publicado: (2019)

Molecular markers of neuropsychological functioning and Alzheimer's disease
por: Edwards, Melissa, et al.
Publicado: (2015)

A blood screening test for Alzheimer's disease
por: O'Bryant, Sid E., et al.
Publicado: (2016)

Differential blood DNA methylation across Lewy body dementias
por: Nasamran, Chanond A., et al.
Publicado: (2021)

Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges
por: O'Bryant, Sid E., et al.
Publicado: (2015)

Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort
por: Gupta, Veer Bala, et al.
Publicado: (2017)

Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort
por: Gonzales, Mitzi M., et al.
Publicado: (2022)

Plasma BDNF levels associate with Pittsburgh Compound B binding in the brain
por: Hwang, Kristy S., et al.
Publicado: (2015)

The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment
por: Klavins, Kristaps, et al.
Publicado: (2015)

Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology
por: Savica, Rodolfo, et al.
Publicado: (2016)

Amyloid-β sequester proteins as blood-based biomarkers of cognitive decline
por: Uchida, Kazuhiko, et al.
Publicado: (2015)

Blood protein predictors of brain amyloid for enrichment in clinical trials?
por: Ashton, Nicholas J., et al.
Publicado: (2015)

Reduced plasma desmosterol-to-cholesterol ratio and longitudinal cognitive decline in Alzheimer's disease
por: Sato, Yoshiaki, et al.
Publicado: (2015)

Repeated systemic inflammation was associated with cognitive deficits in older Britons
por: Tampubolon, Gindo
Publicado: (2015)

MicroRNA deregulation and chemotaxis and phagocytosis impairment in Alzheimer's disease
por: Guedes, Joana R., et al.
Publicado: (2015)

Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers
por: DeMarshall, Cassandra A., et al.
Publicado: (2016)

Thrombopoietin is associated with δ's intercept, and only in Non-Hispanic Whites
por: Royall, Donald R., et al.
Publicado: (2016)

Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging
por: Gupta, Veer Bala, et al.
Publicado: (2015)

Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker
por: Oh, Esther S., et al.
Publicado: (2015)

Prospective associations of plasma phospholipids and mild cognitive impairment/dementia among African Americans in the ARIC Neurocognitive Study
por: Li, Danni, et al.
Publicado: (2016)

Plasma clusterin levels and risk of dementia, Alzheimer's disease, and stroke
por: Weinstein, Galit, et al.
Publicado: (2016)

Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile
por: Winston, Charisse N., et al.
Publicado: (2016)

Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the ARIC Neurocognitive Study (ARIC-NCS)
por: Li, Danni, et al.
Publicado: (2016)

Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis
por: Janssens, Jana, et al.
Publicado: (2018)

Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals
por: Fandos, Noelia, et al.
Publicado: (2017)

Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles
por: Keshavan, Ashvini, et al.
Publicado: (2018)

Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease
por: Peloso, Gina M., et al.
Publicado: (2018)

Apolipoproteins and Alzheimer's pathophysiology
por: Koch, Manja, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gu11p6gkq34lnepl76g8o8k4a6